Tags

Type your tag names separated by a space and hit enter

Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study.
Eur J Gastroenterol Hepatol 1995; 7(5):419-26EJ

Abstract

OBJECTIVE

To identify risk factors for gastrointestinal bleeding (GIB) among users of non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs).

DESIGN

Case-control study.

PARTICIPANTS

A total of 120 patients aged over 60 years and using NANSAIDs were hospitalized between January 1988 and September 1992 for GIB related to erosions or ulceration of the gastroduodenal mucosa. A group of 100 general practitioners selected two controls matched for age and sex, receiving NANSAIDs and without GIB, for each patient.

METHODS

The same questionnaire was used to interview patients and controls about their medical history, use of NANSAIDs and other drugs, alcohol and tobacco use, recent stress and nutritional status.

RESULTS

The adjusted odds ratios (OR) for the risk factors related to the pattern of NANSAID use were 3.39 [95% confidence interval (CI) 1.77-6.47] when the intake of NANSAIDs was followed by decubitus, 3.00 (95% CI 1.54-5.85) when NANSAIDs were taken before a meal, 6.05 (95% CI 2.10 17.43) with a high dose of NANSAIDs, 5.87 (95% CI 2.00-17.25) with recent NANSAID use, 3.35 (95% CI 1.47-7.64) with NANSAIDs associated with aspirin use, 3.46 (95% CI 1.15-10.36) with more than one NANSAID, and 10.70 (95% CI 1.06-108.07) when NANSAIDs were associated with corticosteroids. The patient-related risk factors and their OR were 9.94 (95% CI 3.29-24.28) for irregular food intake, 3.94 (95% CI 1.45-10.69) for previous peptic ulcer, 3.71 (95% CI 1.26-10.89) for recent weight loss, 4.44 (95% CI 1.48-13.30) for heavy alcohol abuse, 2.92 (95% CI 1.36-6.26) for recent stress and 5.26 (95% CI 1.19-23.33) for a past history of GIB.

CONCLUSION

This study identified a group at 'high risk' for GIB which would benefit from the development of a prophylactic therapy.

Authors+Show Affiliations

Biochemistry and Digestive Physiopathology and Nutrition Group, Charles Nicolle Hospital, Rouen, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7614104

Citation

Hochain, P, et al. "Which Patients Taking Non-aspirin Non-steroidal Anti-inflammatory Drugs Bleed? a Case-control Study." European Journal of Gastroenterology & Hepatology, vol. 7, no. 5, 1995, pp. 419-26.
Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol. 1995;7(5):419-26.
Hochain, P., Berkelmans, I., Czernichow, P., Duhamel, C., Tranvouez, J. L., Lerebours, E., & Colin, R. (1995). Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. European Journal of Gastroenterology & Hepatology, 7(5), pp. 419-26.
Hochain P, et al. Which Patients Taking Non-aspirin Non-steroidal Anti-inflammatory Drugs Bleed? a Case-control Study. Eur J Gastroenterol Hepatol. 1995;7(5):419-26. PubMed PMID: 7614104.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. AU - Hochain,P, AU - Berkelmans,I, AU - Czernichow,P, AU - Duhamel,C, AU - Tranvouez,J L, AU - Lerebours,E, AU - Colin,R, PY - 1995/5/1/pubmed PY - 1995/5/1/medline PY - 1995/5/1/entrez SP - 419 EP - 26 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 7 IS - 5 N2 - OBJECTIVE: To identify risk factors for gastrointestinal bleeding (GIB) among users of non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs). DESIGN: Case-control study. PARTICIPANTS: A total of 120 patients aged over 60 years and using NANSAIDs were hospitalized between January 1988 and September 1992 for GIB related to erosions or ulceration of the gastroduodenal mucosa. A group of 100 general practitioners selected two controls matched for age and sex, receiving NANSAIDs and without GIB, for each patient. METHODS: The same questionnaire was used to interview patients and controls about their medical history, use of NANSAIDs and other drugs, alcohol and tobacco use, recent stress and nutritional status. RESULTS: The adjusted odds ratios (OR) for the risk factors related to the pattern of NANSAID use were 3.39 [95% confidence interval (CI) 1.77-6.47] when the intake of NANSAIDs was followed by decubitus, 3.00 (95% CI 1.54-5.85) when NANSAIDs were taken before a meal, 6.05 (95% CI 2.10 17.43) with a high dose of NANSAIDs, 5.87 (95% CI 2.00-17.25) with recent NANSAID use, 3.35 (95% CI 1.47-7.64) with NANSAIDs associated with aspirin use, 3.46 (95% CI 1.15-10.36) with more than one NANSAID, and 10.70 (95% CI 1.06-108.07) when NANSAIDs were associated with corticosteroids. The patient-related risk factors and their OR were 9.94 (95% CI 3.29-24.28) for irregular food intake, 3.94 (95% CI 1.45-10.69) for previous peptic ulcer, 3.71 (95% CI 1.26-10.89) for recent weight loss, 4.44 (95% CI 1.48-13.30) for heavy alcohol abuse, 2.92 (95% CI 1.36-6.26) for recent stress and 5.26 (95% CI 1.19-23.33) for a past history of GIB. CONCLUSION: This study identified a group at 'high risk' for GIB which would benefit from the development of a prophylactic therapy. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/7614104/Which_patients_taking_non_aspirin_non_steroidal_anti_inflammatory_drugs_bleed_A_case_control_study_ L2 - https://medlineplus.gov/gastrointestinalbleeding.html DB - PRIME DP - Unbound Medicine ER -